To whom much valuation is given, much is expected. That's about the only sense in which Novo Nordisk (NVO)
disappointed anybody this quarter. While this highly-focused
pharmaceutical company has been enjoying phenomenal success in diabetes,
investors may just want to check into the estimates that underpin the
valuation before committing their capital to these shares.
Please follow this link for more:
Novo Nordisk Finally Looks (Slightly) Mortal
No comments:
Post a Comment